The FDA has authorized the ArteraAI Prostate Test to prognosticate long-term outcomes in patients with non-metastatic prostate cancer.

“he introduction of effective cancer innovations increased population-level health among patients with advanced lung cancer and melanoma but also widened the survival gap across county-level income ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ifinatamab deruxtecan (I-DXd) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC ...

An analysis of more than 13 million EHR notes revealed evidence suggesting racial bias in how doctors document patient credibility.

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

The FDA has granted fast track designation to HLD-0915 for the treatment of metastatic castration-resistant prostate cancer.

Subspecialization in oncology is increasing in the United States, but it varies across cancer types and regions, data suggest.

The ASPR must update its 2022 list of 86 essential medicines and provide a plan to store and maintain a 6-month supply of APIs for drugs on the updated list, the order states.

Two researchers describe their experiences with cancer research funding cuts due to the Trump administration’s policies and actions.

Fifty-four percent of Americans surveyed said they drink alcohol — the lowest rate Gallup has recorded in nearly 90 years of tracking.

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.